

Director's Conference

New Insights into the Molecular Pathogenesis of Human Prostate Cancer

Presented by:

William G. Nelson, MD, PhD

Director

*The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD*

Host: Donald Trump, MD, FACP

President & CEO

Roswell Park Cancer Institute

Wednesday, March 4, 2009

8:00 – 9:00 am

Roswell Park Cancer Institute

Center for Genetics and Pharmacology, Zebro Family Conference Center

At the conclusion of the program, participants should be able to:

- ◆ Describe how prostate cancers become addicted to androgenic hormones for growth and survival;
 - ◆ Explain the mechanisms by which prostate cancers progress despite treatment targeting androgen receptor signaling;
 - ◆ Discuss recent advances in the treatment of androgen-independent prostate cancer.
-

ATTENTION: YOU MUST SIGN THE ATTENDANCE SHEET TO RECEIVE CME CREDIT.

Roswell Park Cancer Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Roswell Park Cancer Institute designates this educational activity for a maximum of 1 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Dr. Nelson is a consultant for GlaxoSmithKline and Proquest Investments. He is a major shareholder in Proquest investment. Dr. Nelson has intellectual property licensed to Cell Genesys, OncoMethylome, Stroncor and LabCorp.